Docetaxel: Assessing a range of activity

Anti-Cancer Drugs

Volumn 12, Issue SUPPL. 1, 2001, Pages

  Aapro, M ^a   Rowinsky, E ^a  

^a CLINIQUE DE GENOLIER   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ESTRAMUSTINE; FLUOROURACIL; FOLINIC ACID; MITOXANTRONE; PREDNISONE;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CONFERENCE PAPER; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; HEAD AND NECK CANCER; HUMAN; LUNG NON SMALL CELL CANCER; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CLINICAL TRIALS, PHASE III; HUMANS; NEOPLASMS; PACLITAXEL; TAXOIDS;

EID: 0035057056     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (17)

1. Chemotherapy of breast cancer: Are the taxanes going to change the natural history of breast cancer?
2. Docetaxel (Taxotere) in HER-2-positive patients and in combination with Trastuzumab (Herceptin)
3. Prospective randomized trial of docetaxel versus mitomycin C plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy
4. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: A randomised phase III study with crossover on progression by the Scandinavian Breast Group
5. Taxotere versus 5-fluorouracil plus navelbine in patients with metastatic breast cancer as 2nd line chemotherapy: A phase III study
6. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer
7. A phase III trial comparing doxorubicin and docetaxel to doxorubicin and cyclophosphamide as first-line therapy for MBC
8. Docetaxel in the management of advanced non-small cell lung cancer
9. Docetaxel in combination with platinums in patients with non-small cell lung cancer: Trial data and implications for clinical management
10. A prospective randomized trial of docetaxel (Taxotere®) versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy
11. 2) versus vinorelbine (V) or ifosfamide (I) in non small cell lung cancer (NSCLC) patients, previously treated with a platinum-based chemotherapy
12. A multicenter, randomized, phase III study of docetaxel plus best supportive care in chemotherapy-naïve patients with metastatic or non-resectable non-small cell lung cancer (NSCLC)
13. Docetaxel in combination with fluorouracil for advanced solid tumors
14. Docetaxel: An active drug for squamous cell carcinoma of the head and neck
15. Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: A phase I/II trial
16. A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: Preliminary results of cancer and leukemia group B Trial 9780
17. Response and preliminary survival results of a phase II study of docetaxel (D) + estramustine (E) in patients (pts) with androgen-independent prostate cancer (AIPCA)